Cover Image
市場調查報告書

中樞神經系統 (CNS) 生物標記的全球市場:考察,機會,分析,市場佔有率,未來預測 (2016∼2022年)

Global Central Nervous System (CNS) Biomarkers Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 - 2022

出版商 Occams Business Research & Consulting Pvt. Ltd. 商品編碼 358653
出版日期 內容資訊 英文 140 Pages
商品交期: 請詢問到貨日
價格
Back to Top
中樞神經系統 (CNS) 生物標記的全球市場:考察,機會,分析,市場佔有率,未來預測 (2016∼2022年) Global Central Nervous System (CNS) Biomarkers Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 - 2022
出版日期: 2016年06月05日 內容資訊: 英文 140 Pages
簡介

全球中樞神經系統 (CNS) 生物標記市場,預計2016∼2022年以10.4%的年複合成長率 (CAGR) 成長。市場成長的主要推動因素,是來自政府和民營企業的資金,及基因學、影像設備的發展,迅速的人口高齡化,PPP (公私合營) 的數量增加等。還有預期亞太地區還未開發的市場,及各國政府的輔助體制,今後將導致市場機會的擴大。

本報告提供全球中樞神經系統 (CNS) 生物標記的市場相關分析,關於整體市場結構和背景情況,主要的推動及阻礙市場要素,各用途、各類型、各終端用戶、各地區的市場趨勢預測,主要企業簡介等調查評估。

第1章 簡介

第2章 市場概要

  • 市場定義和範圍
  • 分析的要點
  • 市場指標分析
    • 老年癡呆症的盛行率、發病率
    • 全球各地醫院數、研究機關數
    • 帕金森氏症的盛行率、發病率
    • 癌症的盛行率、發病率
    • 全球各地的醫療費用支出額
  • 市場相關主要考察
    • 新興市場國前幾名3個國家
    • 收益衍生額前幾名3部門
    • 主要的成長市場
    • 主要3個地區
  • 市場競爭相關資訊
    • 市場佔有率分析
    • 主要的成功策略
    • 案例研究:主要企業趨勢
  • 市場競爭相關資訊
    • 市場佔有率分析
    • 主要的成功策略
    • 案例研究:主要企業趨勢
  • 波特的五力分析
  • 主要的購買標準
  • 策略性建議
  • 結論

第3章 對市場的影響要素

  • 推動市場要素
    • 蛋白質體學、基因學、影像設備的開發
    • 來自政府、民營企業的資金供給
    • 文明病的擴大
    • PPP (公私合營) 的數量增加
    • 對由於FDA (美國食品藥物管理局) 的認證:生物標記的大幅關注
    • 技術進步的市場擴大
    • 革新的市場推動成長
    • 全球各國的醫療費用支出的增加
  • 阻礙市場要素
    • CNS生物標記、診斷藥的費用高
    • 醫療費償付的問題與其影響
  • 市場機會
    • 個人化醫療的普及
    • 在未開發的亞太地區擴大,巨大的
    • 隨著全球各國的老年人增加,出現巨大的市場機會
    • 各國政府的良好政策與支援體制
  • 課題
    • CNS生物標記的知名度的提升
    • 全球經濟的低迷的不良影響
    • 樣品收集、儲存的技術問題
  • 母體市場
  • 競爭市場
  • 替代的市場

第4章 市場區分

  • 各用途的市場區隔 (以金額為準,總計9年份)
    • 診斷藥的開發
    • 藥物研發
    • 個人化醫療
    • 疾病風險評估
    • 其他
  • 各種類的市場區隔 (以金額為準,總計9年份)
    • 安全性生物標記的市場
    • 藥理生物標記的市場
    • 預測生物標記的市場
    • 替代生物標記的市場
    • 藥效學生物標記的市場
    • 預後生物標記的市場
    • 認證生物標記的市場
  • 終端用戶的市場區隔 (以金額為準,總計9年份)
    • 醫院市場
    • 眼科診所市場
    • 診療所市場
    • 患者市場

第5章 各地區分析

  • 北美市場 (以金額為準,總計9年份)
    • 美國
    • 加拿大
  • 歐洲市場 (以金額為準,總計9年份)
    • 英國
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 其他
  • 亞太地區市場 (以金額為準,總計9年份)
    • 印度
    • 中國
    • 日本
    • 其他
  • 其他的國家 (RoW) 的市場 (以金額為準,總計9年份)
    • 南美
    • 中東、北非
    • 非洲

第6章 企業簡介 (概要,SCOT分析,策略概況)

  • ABASTAR MDX INC
  • ABIANT INC
  • ACUMEN PHARMACEUTICALS INC
  • ADLYFE INC
  • ALSERES PHARMACEUTICALS INC
  • APITOPE INTERNATIONAL
  • APOSENSE
  • APPLIED NEUROSOLUTIONS INC
  • AVACTA GROUP PLC
  • AVID RADIOPHARMACEUTICALS INC
  • BANYAN BIOMARKERS
  • DIAGENIC ASA
  • EKFDIAGNOSTICS HOLDINGS INC
  • ENZO BIOCHEM INC
  • EXONHIT THERAPEUTICS
  • GENENEWS LTD
  • GLYCOMINDS LTD
  • GREAT LAKES NEUROTECHNOLOGIES
  • INNOGENETICS BIOLOGICALS
  • INNOVATIVE NEUROTECHNOLOGIES INC
  • MERC & CO. IN
  • METABOLON INC
  • MYRIAD RBM INC
  • OLIGOMERIX INC
  • OPKO HEALTH INC
  • OSTA BIOTECHNOLOGIES INC
  • PROTEOME SCIENCES PRODUCTS
  • PSYNOVA NEUROTECH LTD
  • RIDGE DIAGNOSTICS
  • SABIOSCIENCES
  • SATORI PHARMACEUTICAL INC
  • THERMO FISHER SCIENTIFIC

第7章 表格一覽

第8章 圖的一覽

目錄
Product Code: HBI-2031115

A biomarker is a biological feature that are used to measure the biological state, presence of diseases or progress of effects of treatment. It helps in understanding various chronic diseases, its effects on exposure to certain environmental conditions and also in identification of people who are at high risk of developing the same disease being diagnosed. The demand for CNS biomarker has increased with the development of in proteomics, genomics and imaging system, which is a major drivers of the Global Central Nervous System Biomarkers Market. The global CNS biomarker market is witnessing a moderate to high growth in the recent years and is expected to continue so on in the near future. The global CNS biomarker market is expected to reach up to $ 6.2 billion by 2022 growing at 10.4% CAGR during 2016-2022.

The major factors identified that are driving the CNS biomarker market are support from private players and government for increased research and development, development of genomics and imaging system, rapidly increasing aging population and increased public private partnerships. Recently, FDA has approved use CNS biomarkers which has led to its significant growth in the North American region. The world is experiencing a significant growth in aging population. As per Administration for Community Living, population aged 65 and above is estimated to reach more than 80 million by 2050, which is twice of that estimated in 2012.This growth in aging population is leading to increased development of many CNS disorders like Parkinson's, Alzheimer's disease and multiple sclerosis. As per the Aging Research Center, approximately 24 million people are affected with Alzheimer's disease globally. Governments are supporting and funding private and public laboratories to overcome this research and development program across the country. In addition, technological advancements and innovations, development of new applications areas, increasing lifestyle oriented diseases etc. are few factors which are likely to spur the demand of global CNS biomarker market. . Nevertheless, the increasing demand of personalized medicines, large untapped market in emerging economies of APAC and favorable government policies are the few opportunities area for the global CNS biomarker market.

The Global Central Nervous System Biomarkers market is segmented on the basis of type, applications and end users. On the basis of type the market is segmented safety biomarker, efficacy biomarker, predictive biomarker, pharmacodynamic biomarker, prognostic biomarker and validation biomarker. On the basis of application it is segmented as diagnostic development, drug discovery and development, personalized medicine market, disease risk assessment market and other market. In the application segment personalized medicine market is expected to have a significant growth due to its increasing demand by patients. The end-use industry segments comprise the Hospitals, eye clinics, diagnostic centers and patients. The major regional segments analyzed in the report include North America, Europe, Asia Pacific, and Rest of the World with further bifurcation of them on country level, which includes U.S, Canada, India, China, Japan, Germany, U.K., Spain, Brazil etc. Asia Pacific is anticipated to be one the fastest growing market in the global CNS biomarker market. The major reason for high growth is wide customer base in the region, improving healthcare infrastructure, purchasing power of buyers and increasing government initiatives. However at present, North America has the largest market share in global CNS biomarker marker because in the region healthcare infrastructure is more advanced than any other and also because of increasing ageing population. For instance, according to the U.S. Census Bureau approximately 20% of the U.S. population is projected to be 65 years and above by 2030.Some of the key market players are Abiant Inc., Acumen Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Apitope International, Aposense, Avacta Group Plc, Banyan Biomarkers, Diagenic ASA, EKFDiagnostics Holdings Inc., Enzo Biochem Inc., Exonhit Therapeutics, Genenews Ltd, Great Lakes Neuro Technologies, Innogenetics Biological, Innovative Neuro Technologies Inc., Metabolon Inc., Myriad RBM Inc., Oligomerix Inc., Opko Health Inc., Proteome Sciences Products, Psynova Neurotech Ltd, Ridge Diagnostics, Sabiosciences, Satori Pharmaceutical Inc. And Thermo Fisher Scientific. Expansions, Mergers & acquisition and collaborations for product development are the key strategies adopted by the market players to sustain in the market also companies are applying for patents for any new product they develop. In January 2016, D Banyan Biomarkers into an agreement to develop and commercialize hand held blood test to evaluate and detect concussions. With this collaboration Banyan Biomarkers will be able utilize its knowledge of bio molecules responsible for neurological injuries and take an advantage of Philips' strength in handheld diagnostic and patient monitoring technologies. Similarly in February 2014, in a deal of $270 million cash Myriad genetics acquired Crescendo Bioscience. By this acquisition Myriad will be able to use Crescendo Bioscience's Vectra DA test which is used to measure level of disease activity in a patient suffering from rheumatoid arthritis.

Table of Contents

1. INTRODUCTION

  • 1.1. EXECUTIVE SUMMARY
  • 1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW

  • 2.1. MARKET DEFINITION AND SCOPE
  • 2.2. KEY FINDINGS
  • 2.3. PARAMETRIC ANALYSIS
    • 2.3.1. PREVALENCE & INCIDENCE RATE OF ALZHEIMER'S DISEASE
    • 2.3.2. HOSPITAL AND RESEARCH CENTER ACROSS GEOGRAPHIES
    • 2.3.3. PREVALENCE & INCIDENCE RATE OF PARKINSON'S DISEASE
    • 2.3.4. PREVALENCE & INCIDENCE RATE OF CANCER DISEASE
    • 2.3.5. HEALTHCARE EXPENDITURE ACROSS GEOGRAPHIES
  • 2.4. KEY MARKET INSIGHTS
    • 2.4.1. TOP 3 EMERGING COUNTRIES
    • 2.4.2. TOP 3 REVENUE GENERATING SEGMENTS
    • 2.4.3. TOP GROWING MARKETS AND EMERGING TRENDS
    • 2.4.4. TOP 3 GEOGRAPHY
  • 2.5. COMPETITIVE LANDSCAPE
    • 2.5.1. MARKET SHARE ANALYSIS
    • 2.5.2. TOP WINNING STRATEGIES
    • 2.5.3. CASE STUDIES: TOP COMPETITIVE MOVES
  • 2.6. PORTER'S FIVE FORCE MODEL
    • 2.6.1. THREAT OF NEW ENTRANTS
    • 2.6.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
    • 2.6.3. BARGAINING POWER OF BUYER
    • 2.6.4. BARGAINING POWER OF SUPPLIER
    • 2.6.5. INTENSITY OF COMPETITIVE RIVALRY
  • 2.7. KEY BUYING CRITERIA
  • 2.8. STRATEGIC RECOMMENDATION
  • 2.9. STRATEGIC CONCLUSIONS

3. MARKET DETERMINANTS

  • 3.1. MARKET DRIVERS
    • 3.1.1. DEVELOPMENT IN PROTEOMICS, GENOMICS AND IMAGING SYSTEM HAS INCREASED DEMAND FOR CNS BIOMARKER.
    • 3.1.2. FUNDING FROM GOVERNMENT AND PRIVATE PLAYERS TO BOOST CNS BIOMARKER MARKET
    • 3.1.3. GROWTH IN LIFE STYLE ORIENTED DISEASES
    • 3.1.4. GROWTH IN GOVERNMENT AND PRIVATE FUNDING IN CNS BIOMARKER MARKET
    • 3.1.5. GROWTH IN PUBLIC-PRIVATE PARTNERSHIP
    • 3.1.6. FDA APPROVALS GIVING RISE TO SIGNIFICANT SCOPE IN BIOMARKER MARKET
    • 3.1.7. TECHNOLOGICAL ADVANCEMENT ENABLES TO EXPAND CNS BIOMARKER MARKET
    • 3.1.8. INNOVATION GIVING RISE TO GROWTH OF CNS BIOMARKER MARKET
    • 3.1.9. GLOBAL INCREASE IN HEALTHCARE EXPENDITURE
  • 3.2. MARKET RESTRAINTS
    • 3.2.1. HIGH COST OF CNS BIOMARKER TEST AND DIAGNOSTICS
    • 3.2.2. REIMBURSEMENT ISSUES AFFECTING THE CNS BIOMARKER MARKET
  • 3.3. MARKET OPPORTUNITIES
    • 3.3.1. INCREASING ADOPTION OF PERSONALIZED MEDICINES
    • 3.3.2. UNTAPPED APAC REGION HAS HUGE SCOPE FOR CNS BIOMARKER MARKET
    • 3.3.3. GLOBAL INCREASE IN AGING POPULATION HAS CREATED HUGE SCOPE FOR CNS BIOMARKER MARKET
    • 3.3.4. FAVORABLE GOVERNMENT POLICIES AND SUPPORT FOR CNS BIOMARKERS
  • 3.4. MARKET CHALLENGES
    • 3.4.1. CREATING AWARENESS FOR CNS BIOMARKER MARKET
    • 3.4.2. GLOBAL ECONOMIC SLOWDOWN MAY AFFECT THE CNS BIOMARKER MARKET
    • 3.4.3. TECHNICAL ISSUES OF SAMPLE COLLECTION AND STORAGE
  • 3.5. PARENT MARKET
  • 3.6. COMPETITORS MARKET
  • 3.7. ALTERNATIVE MARKET

4. MARKET SEGMENTATION

  • 4.1. GLOBAL CNS BIOMARKER MARKET BY APPLICATION, 2014-2022,($ MILLIONS)
    • 4.1.1. GLOBAL DIAGNOSTIC DEVELOPMENT MARKET, 2014-2022,($ MILLIONS)
    • 4.1.2. GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET, 2014-2022,($ MILLIONS)
    • 4.1.3. GLOBAL PERSONALIZED MEDICINE MARKET, 2014-2022,($ MILLIONS)
    • 4.1.4. GLOBAL DISEASE RISK ASSESSMENT MARKET, 2014-2022,($ MILLIONS)
    • 4.1.5. GLOBAL OTHER MARKET , 2014-2022,($ MILLIONS)
  • 4.2. GLOBAL CNS BIOMARKER MARKET BY TYPE, 2014-2022,($ MILLIONS)
    • 4.2.1. GLOBAL SAFETY BIOMARKER MARKET , 2014-2022,($ MILLIONS)
    • 4.2.2. GLOBAL EFFICACY BIOMARKER MARKET, 2014-2022,($ MILLIONS
    • 4.2.3. GLOBAL PREDICTIVE BIOMARKER MARKET, 2014-2022,($ MILLIONS)
    • 4.2.4. GLOBAL PHARMACODYNAMIC BIOMARKER MARKET, 2014-2022,($ MILLIONS)
    • 4.2.5. GLOBAL PROGNOSTIC BIOMARKER MARKET, 2014-2022,($ MILLIONS)
    • 4.2.6. GLOBAL VALIDATION BIOMARKER MARKET, 2014-2022,($ MILLIONS)
  • 4.3. GLOBAL CNS BIOMARKER MARKET BY END USERS, 2014-2022,($ MILLIONS)
    • 4.3.1. GLOBAL CNS BIOMARKER MARKET BY HOSPITALS, 2014-2022,($MILLIONS)
    • 4.3.2. GLOBAL CNS BIOMARKER MARKET BY EYE CLINICS, 2014-2022,($MILLIONS)
    • 4.3.3. GLOBAL CNS BIOMARKER MARKET BY DIAGNOSTIC CENTERS, 2014-2022,($MILLIONS)
    • 4.3.4. GLOBAL CNS BIOMARKER MARKET BY PATIENTS, 2014-2022,($MILLIONS)

5. GEOGRAPHICAL ANALYSIS

  • 5.1. NORTH AMERICA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
    • 5.1.1. UNITED STATES (U.S.) CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
    • 5.1.2. CANADA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 5.2. EUROPE CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
    • 5.2.1. UNITED KINGDOM (UK) CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
    • 5.2.2. FRANCE CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
    • 5.2.3. GERMANY CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
    • 5.2.4. SPAIN CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
    • 5.2.5. ITALY CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
    • 5.2.6. ROE CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 5.3. ASIA PACIFIC CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
    • 5.3.1. INDIA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
    • 5.3.2. CHINA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
    • 5.3.3. JAPAN CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
    • 5.3.4. ROAPAC CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 5.4. REST OF THE WORLD CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
    • 5.4.1. LATIN AMERICA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
    • 5.4.2. MENA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
    • 5.4.3. AFRICA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)

6. COMPANY PROFILING: - (OVER, SCOT ANALYSIS, STRATEGIC REVIEW)

  • 1. ABASTAR MDX INC
  • 2. ABIANT INC
  • 3. ACUMEN PHARMACEUTICALS INC
  • 4. ADLYFE INC
  • 5. ALSERES PHARMACEUTICALS INC
  • 6. APITOPE INTERNATIONAL
  • 7. APOSENSE
  • 8. APPLIED NEUROSOLUTIONS INC
  • 9. AVACTA GROUP PLC
  • 10. AVID RADIOPHARMACEUTICALS INC
  • 11. BANYAN BIOMARKERS
  • 12. DIAGENIC ASA
  • 13. EKFDIAGNOSTICS HOLDINGS INC
  • 14. ENZO BIOCHEM INC
  • 15. EXONHIT THERAPEUTICS
  • 16. GENENEWS LTD
  • 17. GLYCOMINDS LTD
  • 18. GREAT LAKES NEUROTECHNOLOGIES
  • 19. INNOGENETICS BIOLOGICALS
  • 20. INNOVATIVE NEUROTECHNOLOGIES INC
  • 21. MERC & CO. IN
  • 22. METABOLON INC
  • 23. MYRIAD RBM INC
  • 24. OLIGOMERIX INC
  • 25. OPKO HEALTH INC
  • 26. OSTA BIOTECHNOLOGIES INC
  • 27. PROTEOME SCIENCES PRODUCTS
  • 28. PSYNOVA NEUROTECH LTD
  • 29. RIDGE DIAGNOSTICS
  • 30. SABIOSCIENCES
  • 31. SATORI PHARMACEUTICAL INC
  • 32. THERMO FISHER SCIENTIFIC

7. LIST OF TABLES

  • 1. GLOBAL DIAGNOSTIC DEVELOPMENT MARKET, 2014-2022,($ MILLIONS)
  • 2. GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET, 2014-2022,($ MILLIONS)
  • 3. GLOBAL PERSONALIZED MEDICINE MARKET, 2014-2022,($ MILLIONS)
  • 4. GLOBAL DISEASE RISK ASSESSMENT MARKET, 2014-2022,($ MILLIONS)
  • 5. GLOBAL OTHER MARKET , 2014-2022,($ MILLIONS)
  • 6. GLOBAL SAFETY BIOMARKER MARKET , 2014-2022,($ MILLIONS)
  • 7. GLOBAL EFFICACY BIOMARKER MARKET, 2014-2022,($ MILLIONS
  • 8. GLOBAL PREDICTIVE BIOMARKER MARKET, 2014-2022,($ MILLIONS)
  • 9. GLOBAL PHARMACODYNAMIC BIOMARKER MARKET, 2014-2022,($ MILLIONS)
  • 10. GLOBAL PROGNOSTIC BIOMARKER MARKET, 2014-2022,($ MILLIONS)
  • 11. GLOBAL VALIDATION BIOMARKER MARKET, 2014-2022,($ MILLIONS)
  • 12. GLOBAL CNS BIOMARKER MARKET BY HOSPITALS, 2014-2022,($MILLIONS)
  • 13. GLOBAL CNS BIOMARKER MARKET BY EYE CLINICS, 2014-2022,($MILLIONS)
  • 14. GLOBAL CNS BIOMARKER MARKET BY DIAGNOSTIC CENTERS, 2014-2022,($MILLIONS)
  • 15. GLOBAL CNS BIOMARKER MARKET BY PATIENTS, 2014-2022,($MILLIONS)
  • 16. NORTH AMERICA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 17. UNITED STATES (U.S.) CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 18. CANADA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 19. EUROPE CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 20. UNITED KINGDOM (UK) CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 21. FRANCE CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 22. GERMANY CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 23. SPAIN CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 24. ITALY CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 25. ROE CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 26. ASIA PACIFIC CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 27. INDIA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 28. CHINA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 29. JAPAN CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 30. ROAPAC CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 31. REST OF THE WORLD CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 32. LATIN AMERICA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 33. MENA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 34. AFRICA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)

8. LIST OF FIGURES

  • 1. GLOBAL DIAGNOSTIC DEVELOPMENT MARKET, 2014-2022,($ MILLIONS)
  • 2. GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET, 2014-2022,($ MILLIONS)
  • 3. GLOBAL PERSONALIZED MEDICINE MARKET, 2014-2022,($ MILLIONS)
  • 4. GLOBAL DISEASE RISK ASSESSMENT MARKET, 2014-2022,($ MILLIONS)
  • 5. GLOBAL OTHER MARKET , 2014-2022,($ MILLIONS)
  • 6. GLOBAL SAFETY BIOMARKER MARKET , 2014-2022,($ MILLIONS)
  • 7. GLOBAL EFFICACY BIOMARKER MARKET, 2014-2022,($ MILLIONS
  • 8. GLOBAL PREDICTIVE BIOMARKER MARKET, 2014-2022,($ MILLIONS)
  • 9. GLOBAL PHARMACODYNAMIC BIOMARKER MARKET, 2014-2022,($ MILLIONS)
  • 10. GLOBAL PROGNOSTIC BIOMARKER MARKET, 2014-2022,($ MILLIONS)
  • 11. GLOBAL VALIDATION BIOMARKER MARKET, 2014-2022,($ MILLIONS)
  • 12. GLOBAL CNS BIOMARKER MARKET BY HOSPITALS, 2014-2022,($MILLIONS)
  • 13. GLOBAL CNS BIOMARKER MARKET BY EYE CLINICS, 2014-2022,($MILLIONS)
  • 14. GLOBAL CNS BIOMARKER MARKET BY DIAGNOSTIC CENTERS, 2014-2022,($MILLIONS)
  • 15. GLOBAL CNS BIOMARKER MARKET BY PATIENTS, 2014-2022,($MILLIONS)
  • 16. NORTH AMERICA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 17. UNITED STATES (U.S.) CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 18. CANADA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 19. EUROPE CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 20. UNITED KINGDOM (UK) CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 21. FRANCE CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 22. GERMANY CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 23. SPAIN CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 24. ITALY CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 25. ROE CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 26. ASIA PACIFIC CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 27. INDIA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 28. CHINA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 29. JAPAN CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 30. ROAPAC CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 31. REST OF THE WORLD CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 32. LATIN AMERICA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 33. MENA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
  • 34. AFRICA CNS BIOMARKER MARKET, 2014-2022, ($MILLIONS)
Back to Top